Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Impetigo Drug Development Pipeline Study, H1 2018 -

Research and Markets
Posted on: 28 Feb 18

The "Impetigo: Drug Development Pipeline Study, H1 2018" report has been added to's offering.

The most comprehensive pipeline review Impetigo- Drug Development Pipeline Study provides in-depth analysis and update information on Impetigo pipeline drugs. Current status of all the drugs in the Impetigo pipeline is provided in the research work.

The report provides detailed analysis of Impetigo pipeline including companies involved, drugs in different stages of development, drug development details across regions (North America, Europe, Asia Pacific and Rest of the World). Further, the Impetigo report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Impetigo industry.

Excerpts from Impetigo- Drug Development Pipeline Study:

Impetigo pipeline comprises of 4 drugs under development as of February 2018. Of these, 2 drugs are in Phase 2 and 1 drug is in phase 2/3. Further, 1 drug is in Pre-Clinical Stage.

No drugs have been granted with Orphan drug designation by FDA/ EMA.

6 companies are developing the pipeline for Impetigo. Of this, all the companies are developing one drug each and the NovaBay Pharmaceuticals, Inc. therapeutic candidate is in Phase 2/3.

During December 2017, Xepi (ozenoxacin cream) of Ferrer Internacional S.A. has been approved. The drug is a DNA topoisomerase inhibitor.

Impetigo is a highly contagious bacterial skin infection that accounts for around one-tenth of all skin problems in the US. The condition is caused primarily by staphylococcal (staph) bacteria and occasionally with streptococcal (strep) bacteria. The bacteria enter the skin and causes impetigo.

Pediatric subjects between 2 and 6 years age are the most affected population. Symptoms typically include sores on face, arms and legs with reddish skin around the sores observed.

Products Mentioned:

  • XF 70 DPD201
  • DPD202
  • DPD204
  • DPD206
  • DPD207
  • DPD241
  • XF-42
  • XF-70
  • FMX 102
  • LTX-109 Lytixar
  • Nobactine
  • Ozenoxacin
  • Auriclosene
  • AgaDerm
  • AgaNase
  • AL-46383A
  • CD-07223

Key Topics Covered:

1 List of Figures & Tables

2 Executive Summary

3 Impetigo - Company Wise Pipeline Analysis

4 Impetigo Pipeline Drug Snapshots

5 Recent Developments in Impetigo Pipeline

6 Appendix

Companies Mentioned

  • Alcon
  • Cipher Pharmaceuticals
  • Destiny Pharma Ltd
  • Ferrer Internacional S.A.
  • Ferrer Maruho
  • Foamix Pharmaceuticals Ltd
  • Galderma
  • Laboratories Ojer Pharma
  • Lytix Biopharma ASA
  • NovaBay Pharmaceuticals, Inc.
  • Toyama Chemical

For more information about this report visit

View source version on

Business Wire

Last updated on: 28/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.